ITRACONAZOLE 100MG

ITRACONAZOLE (SPORANOX) 100MG CAPS 15’S

Vulvovaginal candidosis.

2. Pityriasis versicolor.

3. Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp., Microsporum spp., Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum.

4. Oropharyngeal candidosis.

5. Onychomycosis caused by dermatophytes and/or yeasts.

6. The treatment of histoplasmosis.

7. Sporanox is indicated in the following systemic fungal conditions when first-line systemic anti-fungal therapy is inappropriate or has proved ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

– Treatment of aspergillosis and candidosis

– Treatment of cryptococcosis (including cryptococcal meningitis): in immunocompromised patients with cryptococcosis and in all patients with cryptococcosis of the central nervous system.

– Maintenance therapy for penicilliosis and histoplasmosis only in AIDS patients.

– Maintenance therapy of cryptococcal meninigitis only in AIDS patients when standard therapy is considered inappropriate.

Sporanox is also indicated for prophylaxis of fungal infections in immunocompromised patients with severe neutropenia when standard therapy is considered inappropriate.